|
1
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stenzl A, Cowan NC, De Santis M, Kuczyk
MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JAEuropean
Association of Urology: Treatment of muscle-invasive and metastatic
bladder cancer: Update of the EAU guidelines. Actas Urol Esp.
36:449–460. 2012.(In Spanish).
|
|
3
|
Herr HW, Dotan Z, Donat SM and Bajorin DF:
Defining optimal therapy for muscle invasive bladder cancer. J
Urol. 177:437–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin: Response to
Farooki and Schneider. Diabetes Care. 29:1990–1991. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ropelle ER, Pauli JR, Zecchin KG, Ueno M,
de Souza CT, Morari J, Faria MC, Velloso LA, Saad MJ and
Carvalheira JB: A central role for neuronal adenosine
5′-monophosphate-activated protein kinase in cancer-induced
anorexia. Endocrinology. 148:5220–5229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abdelnour-Berchtold E, Cerantola Y, Roulin
D, Dormond-Meuwly A, Demartines N and Dormond O: Rapamycin-mediated
FOXO1 inactivation reduces the anticancer efficacy of rapamycin.
Anticancer Res. 30:799–804. 2010.PubMed/NCBI
|
|
11
|
Iwata H, Sato H, Suzuki R, Yamada R,
Ichinomiya S, Yanagihara M, Okabe H, Sekine Y, Yano T and Ueno K: A
demethylating agent enhances chemosensitivity to vinblastine in a
xenograft model of renal cell carcinoma. Int J Oncol. 38:1653–1661.
2011.PubMed/NCBI
|
|
12
|
Jensen MM, Jørgensen JT, Binderup T and
Kjaer A: Tumor volume in subcutaneous mouse xenografts measured by
microCT is more accurate and reproducible than determined by
18F-FDG-microPET or external caliper. BMC Med Imaging. 8:162008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rocha GZ, Dias MM, Ropelle ER, et al:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyake M, Anai S, Fujimoto K, et al:
5-fluorouracil enhances the antitumor effect of sorafenib and
sunitinib in a xenograft model of human renal cell carcinoma. Oncol
Lett. 3:1195–1202. 2012.PubMed/NCBI
|
|
16
|
Juffs HG, Moore MJ and Tannock IF: The
role of systemic chemotherapy in the management of muscle-invasive
bladder cancer. Lancet Oncol. 3:738–747. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta S and Mahipal A: Role of systemic
chemotherapy in urothelial urinary bladder cancer. Cancer Control.
20:200–210. 2013.PubMed/NCBI
|
|
18
|
Fonseca EA, de Oliveira MA, Lobato NS,
Akamine EH, Colquhoun A, de Carvalho MH, Zyngier SB and Fortes ZB:
Metformin reduces the stimulatory effect of obesity on in vivo
Walker-256 tumor development and increases the area of tumor
necrosis. Life Sci. 88:846–852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pollack MN: Insulin, insulin-like growth
factors, insulin resistance, and neoplasia. Am J Clin Nutr.
86:s820–s822. 2007.PubMed/NCBI
|
|
20
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: Taking away
the candy for cancer? Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaaks R, Lukanova A and Kurzer MS:
Obesity, endogenous hormones, and endometrial cancer risk: A
synthetic review. Cancer Epidemiol Biomarkers Prev. 11:1531–1543.
2002.PubMed/NCBI
|
|
22
|
Ben Sahra I, Laurent K, Giuliano S,
Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y,
Giorgetti-Peraldi S, Cormont M, Bertolotto C, et al: Targeting
cancer cell metabolism: The combination of metformin and
2-deoxyglucose induces p53-dependent apoptosis in prostate cancer
cells. Cancer Res. 70:2465–2475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harris TE and Lawrence JC Jr: TOR
signaling. Sci STKE. 2003:re152003.PubMed/NCBI
|
|
24
|
Zakikhani M, Blouin MJ, Piura E and Pollak
MN: Metformin and rapamycin have distinct effects on the AKT
pathway and proliferation in breast cancer cells. Breast Cancer Res
Treat. 123:271–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang XL, Zhang Y, Luo CL and Wu XH:
Targeting renal cell carcinoma with gambogic acid in combination
with sunitinib in vitro and in vivo. Asian Pac J Cancer Prev.
13:6463–6468. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brazil DP and Hemmings BA: Ten years of
protein kinase B signalling: A hard Akt to follow. Trends Biochem
Sci. 26:657–664. 2001. View Article : Google Scholar : PubMed/NCBI
|
